Costain selected as delivery partner for Urenco at Capenhurst
announced on Thursday that it has been selected as the programme delivery partner for Urenco's infrastructure investment at its Capenhurst site in Cheshire.
The London-listed firm said the contract, expected to span at least three years, would see it lead and execute a series of upgrades to support Urenco's operations.
It said the Capenhurst facility plays a key role in uranium enrichment for civil nuclear power, supplying fuel for low-carbon electricity generation in the UK and internationally.
The partnership with Costain was part of Urenco's broader investment in modernising its infrastructure to enhance operational efficiency and support long-term growth.
Costain said it would oversee the integration and delivery of various infrastructure improvements, with contracts to be awarded under the framework over the programme's duration.
"Costain has a long and successful track record in delivering critical national infrastructure that creates a sustainable future," said chief executive officer Alex Vaughan.
"This new role is an example of our strategic focus on growth in strong markets and building a resilient customer mix.
"We will draw on our expertise to ensure predictable, best-in-class delivery for Urenco, as we create a more prosperous, resilient and decarbonised UK."
At 0935 GMT, shares in Costain Group were up 0.47% at 106.5p.
Reporting by Josh White for Sharecast.com.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.